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Abstract
Current antibiotics tend to be broad spectrum, leading to indiscriminate killing of commensal 
bacteria and accelerated evolution of drug resistance. Here, we use CRISPR-Cas technology to 
create antimicrobials whose spectrum of activity is chosen by design. RNA-guided nucleases 
(RGNs) targeting specific DNA sequences are delivered efficiently to microbial populations using 
bacteriophage or bacteria carrying plasmids transmissible by conjugation. The DNA targets of 
RGNs can be undesirable genes or polymorphisms, including antibiotic resistance and virulence 
determinants in carbapenem-resistant Enterobacteriaceae and enterohemorrhagic Escherichia coli. 
Delivery of RGNs significantly improves survival in a Galleria mellonella infection model. We 
also show that RGNs enable modulation of complex bacterial populations by selective knockdown 
of targeted strains based on genetic signatures. RGNs constitute a class of highly discriminatory, 
customizable antimicrobials that enact selective pressure at the DNA level to reduce the 
prevalence of undesired genes, minimize off-target effects and enable programmable remodeling 
of microbiota.
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There is mounting concern over the emergence and proliferation of multidrug-resistant 
bacterial pathogens and the dwindling treatment options for these organisms1. Recently, 
carbapenem-resistant Enterobacteriaceae, a group of intestinal Gram-negative bacteria 
known to cause life-threatening opportunistic infections, were highlighted by the US Centers 
for Disease Control and Prevention as one of three most urgent threats among antibiotic-
resistant bacteria1. Carbapenems have traditionally been reserved as a last resort treatment 
for Gram-negative infections, but the spread of extended-spectrum β-lactamases has 
necessitated the increased usage of carbapenems and favored the emergence of carbapenem-
resistant strains refractory toward most or all current treatment options. The responsible 
enzymes, including New-Delhi metallo-β-lactamase 1 (NDM-1), may confer pan-resistance 
to β-lactam antibiotics and are frequently co-harbored with additional resistance 
determinants on mobile plasmids that facilitate rapid dissemination within and beyond 
Enterobacteriaceae2. The diversity of multidrug-resistant bacteria compounds the difficulty 
of developing treatments that target pathogens and commensal reservoirs but avoid 
nonspecific broad-spectrum activity.
Here, we introduce an alternative antimicrobial approach that imposes direct evolutionary 
pressure at the gene level by using efficiently delivered, programmable RGNs. We 
engineered the clustered, regularly interspaced, short palindromic repeats (CRISPR)–
CRISPR-associated (Cas) system, naturally employed in bacteria as a defense strategy 
against mobile elements3,4, to effect cell death or plasmid loss upon detection of genetic 
signatures associated with virulence or antibiotic resistance. The Type II CRISPR-Cas 
system of Streptococcus pyogenes is an effective, programmable tool for genome editing 
and gene expression in a wide variety of organisms5. The specificity of CRISPR-Cas is 
dictated by short, spacer sequences flanked by direct repeats encoded in the CRISPR locus, 
which are transcribed and processed into CRISPR RNAs (crRNA)6. With the aid of a trans-
activating small RNA (tracrRNA), crRNAs enable the Cas9 endonuclease to introduce 
double-stranded breaks in target DNA sequences6,7. Through simple modifications of 
spacers in the CRISPR locus, an RGN can direct cleavage of almost any DNA sequence, 
with the only design restriction being a requisite NGG motif immediately 3′ of the target 
sequence7. By packaging RGNs into bacteriophage particles or harnessing mobilizable 
plasmids, we implemented conditional-lethality devices with high specificity, modularity 
and multiplexability against undesired DNA sequences (Fig. 1a and Supplementary Fig. 1).
To establish RGN functionality in mediating sequence-specific cytotoxicity, we designed 
RGNs to induce double-stranded breaks in blaSHV-18 or blaNDM-1, which encode extended-
spectrum and pan-resistance to β-lactam antibiotics, respectively (Supplementary Table 
1)8,9. Transformation of E. coli by plasmid-borne RGNs (pRGNs) containing a 
chromosomal copy of these target genes resulted in nearly a 1,000-fold decrease in 
transformation efficiency as compared to wild-type cells lacking the target (Supplementary 
Fig. 2a). These results corroborate the mutual exclusivity between a functional crRNA and a 
cognate target locus10,11. Sequence analysis of 30 escape mutants (cells that receive and 
maintain an RGN plasmid despite the presence of a target sequence) revealed that tolerance 
was exclusively due to a defective construct that frequently arose from a spacer deletion 
within the CRISPR locus (Supplementary Fig. 3). Furthermore, deletion of the tracrRNA as 
Citorik et al. Page 2
Nat Biotechnol. Author manuscript; available in PMC 2015 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
well as inactivation of the RuvC-like nuclease domain of Cas9 (D10A)7 abrogated the loss 
of transformation efficiency in cells that harbored a target sequence. Thus, a catalytically 
active endonuclease, tracrRNA and crRNA are necessary and sufficient to mediate 
sequence-specific cytotoxicity in E. coli (Fig. 1a).
Antibiotic resistance genes are often present on large, multicopy plasmids capable of 
autonomous transfer in microbial populations, resulting in horizontal dissemination of drug 
resistance2. RGN activity against high-copy plasmids was verified using a GFP-expressing, 
ColE1-derived vector containing a standard β-lactamase selectable marker (pZE-blaz-gfp)12 
or blaNDM-1 (pZE-blaNDM-1-gfp). Vectors bearing this ColE1 origin are reported to be 
present at copy numbers of 50–70 per cell12. Transformation of cells containing pZE-
blaNDM-1- gfp with pRGNndm-1, a plasmid-borne RGN targeting blaNDM-1, led to a three-
log10 reduction in transformants retaining resistance to the β-lactam antibiotic carbenicillin, 
whereas transformation of cells containing target-free pZE-blaz-gfp with pRGNndm-1 did 
not lead to a reduction in resistant transformants (Supplementary Fig. 2b). The activity of 
RGNs is therefore sufficient to exclude even high-copy antibiotic resistance plasmids from 
cells and can resensitize a resistant population to antibiotics. Similarly, transformation of 
cells possessing pZE-blaNDM-1-gfp with pRGNndm-1 led to an ~1,000-fold decrease in 
GFP-expressing cells, as measured by flow cytometry, but no decrease was found with 
transformation of cells possessing pZE-blaz-gfp with pRGNndm-1 (Supplementary Fig. 4).
The usefulness of RGNs for antimicrobial therapy hinges on high-efficiency delivery of 
genetic constructs to bacterial cells. We explored two mechanisms of horizontal gene 
transfer that are used by bacteria to acquire foreign genetic elements: plasmid conjugation 
and viral transduction. Although constrained by requirements for cell-cell contact, 
conjugative plasmids often have wide host ranges and no recipient factors necessary for 
DNA uptake have been identified13. Efficient transfer of RGNs was achieved using the 
broad-host-range plasmid R1162 mobilized by E. coli S17-1, which contains the conjugative 
machinery of plasmid RP4 integrated into its chromosome. In filter mating experiments, 
conjugative transfer of RGNs resulted in a 40- to 60-fold reduction in target carbenicillin-
resistant recipient cells (Supplementary Fig. 1b). Under selection for transconjugants, 
transfer of RGNs into recipients yielded a 2- to 3-log10 reduction in target cells as compared 
to controls, suggesting that conjugation efficiency, as opposed to RGN activity, limited 
RGN efficacy in this context (Supplementary Fig. 1c). Future work will be necessary to 
further optimize the efficiency of conjugation-based delivery vehicles for antimicrobials 
based on mobilizable RGNs.
Bacteriophages are natural predators of bacteria and are highly adept at injecting DNA into 
host cells. To adapt phage for RGN delivery, we engineered phagemid vectors by pairing 
RGN constructs targeting blaNDM-1 or blaSHV-18 with an f1 origin to facilitate packaging 
into M13 particles. Phage-packaged RGNndm-1 (ΦRGNndm-1) was capable of 
comprehensively transducing a population of E. coli EMG2 (Supplementary Fig. 5). To test 
the ΦRGNs, we conjugated native plasmids containing blaNDM-1 (pNDM-1) or blaSHV-18 
(pSHV-18) from clinical isolates into EMG2. Treatment of the EMG2 pNDM-1 or EMG2 
pSHV-18 strains with the cognate ΦRGNs resulted in 2- to 3-log10 reductions in viable cells 
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even in the absence of any selection (Fig. 1b). Furthermore, ΦRGNs engendered no toxicity 
against wild-type EMG2 or EMG2 containing noncognate plasmids (Fig. 1b).
In naturally occurring Type II CRISPR-Cas systems, the CRISPR locus may contain 
multiple spacers, each of which is processed into an independent crRNA molecule that, with 
tracrRNA, enables Cas9 to cleave cognate DNA sequences6. To explore the utility of a 
single ΦRGN exhibiting activity against more than one genetic signature, we engineered a 
construct containing two spacers encoding two different crRNAs for targeting the blaNDM-1 
and blaSHV-18 resistance genes (ΦRGNndm-1/shv-18). ΦRGNndm-1/shv-18 generated 2- to 
3-log10 reductions in viable cells of EMG2 pNDM-1 or EMG2 pSHV-18, but not of wild-
type EMG2 (Fig. 1b). Thus, RGNs may be multiplexed against different genetic signatures, 
enabling simultaneous targeting of a variety of virulence factors and resistance genes that 
may exist in microbial populations.
In addition to antibiotic-modifying enzymes, such as β-lactamases, alterations in host 
proteins constitute a major antibiotic resistance mechanism in bacteria14. Owing to the 
specificity of the CRISPR-Cas system, we suspected that RGNs might discriminate between 
susceptible and resistant strains that differ by a single-nucleotide mutation in DNA gyrase 
(gyrA), which confers resistance to quinolone antibiotics (Supplementary Table 1)14. Indeed, 
ΦRGNgyrAD87G was specifically cytotoxic only for quinolone-resistant E. coli harboring the 
chromosomal gyrAD87G mutation and not for otherwise isogenic strains with the wild-type 
gyrA gene (Fig. 1c).
Killing curves revealed that ΦRGNs mediated rapid killing of target cells, with viable cell 
counts that decayed exponentially (t1/2 ~ 13 min) and maximal bactericidal effect was 
achieved by 2–4 h (Fig. 2a). Moreover, ΦRGN antimicrobial activity increased with 
phagemid particle concentration (Fig. 2b and Supplementary Fig. 6). To further characterize 
the cellular response to RGN-mediated targeting, we assessed treatment of cells that 
harbored a GFP reporter under SOS regulation. E. coli and other bacteria respond to 
chromosomal double-stranded breaks, including those artificially generated by the 
meganuclease I-SceI, by inducing DNA repair through the activation of the SOS response15. 
We observed a 2.6- or 4.0-fold increase in fluorescence in cells containing the reporter 
plasmid and a plasmid-borne (blaNDM-1) or chromosomal (gyrAD87G) target site, 
respectively, when treated with the cognate versus noncognate ΦRGNs (Supplementary Fig. 
7). These results confirm that RGNs can induce DNA damage in target cells and 
demonstrate that they can be coupled with SOS-based reporters to detect specific genes or 
sequences, even at the single-nucleotide level.
We were intrigued to observe that targeted cleavage of blaNDM-1 with ΦRGNndm-1 in the 
context of the native plasmid was lethal to host cells, whereas targeted cleavage of the same 
gene in a standard cloning vector was not (‘pNDM-1’ versus ‘pZA-ndm1-gfp’, respectively, 
in Fig. 2c). Therefore, we hypothesized that ΦRGN-induced plasmid loss in itself does not 
elicit lethality, but rather results in cytotoxicity by means of other co-harbored plasmid-
borne functions. Toxin-antitoxin systems are components of natural plasmids that ensure 
their persistence in bacterial populations by inhibiting the growth of daughter cells that do 
not inherit the plasmid. Toxin-antitoxin systems traditionally consist of a labile antitoxin that 
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quenches the activity of a stable toxin. Owing to the differential stability of these two 
components, cessation of gene expression upon plasmid loss leads to depletion of the 
antitoxin pool faster than the toxin pool, resulting in de-repression of toxin activity and, 
ultimately, stasis or programmed cell death16. Analysis of the sequenced pSHV-18 plasmid 
revealed the presence of a single toxin-antitoxin module, pemIK, which is commonly found 
among isolates harboring extended-spectrum β-lactamases17. When complemented with the 
PemI antitoxin expressed constitutively in trans (pZA31-pemI), ΦRGNshv-18 treatment of 
EMG2 pSHV-18 abrogated cytotoxicity and instead resulted in resensitization of this 
multidrug-resistant strain to carbenicillin (Fig. 2d). We attributed this effect to PemI 
inactivation of the PemK toxin, thus enabling loss of the pSHV-18 plasmid without 
concomitant bacterial killing. Toxin-antitoxin systems can therefore dictate the outcome of 
ΦRGN activity on episomal targets, as their presence leads to cytotoxicity and their absence 
or neutralization to plasmid loss.
To further demonstrate the versatility of RGNs for specifically combating pathogens, we 
designed a ΦRGN to target intimin, a chromosomally encoded virulence factor of 
enterohemorrhagic E. coli O157:H7 (EHEC) necessary for intestinal colonization and 
pathology. Encoded by the eae gene, intimin is a cell-surface adhesin that mediates intimate 
attachment to the host epithelium, permitting subsequent disruption of intestinal tight 
junctions and effacement of microvilli18. Treatment of EHEC with ΦRGNeae resulted in a 
20-fold reduction in viable cell counts; this cytotoxicity was increased an additional 100-
fold under kanamycin selection for ΦRGNeae transductants (Fig. 3a). The increase in 
cytotoxicity with selection for cells receiving the construct suggests that the efficacy of 
ΦRGN treatment was limited by delivery in this strain. Furthermore, ΦRGN treatment was 
assessed in G. mellonella larvae, an infection model that yields virulence data often 
predictive for higher-order mammals19. This model has also been used to evaluate the 
efficacy of antimicrobials or phage therapy against various Gram-negative, Gram-positive 
and fungal pathogens19. Administration of ΦRGNeae to EHEC-infected G. mellonella 
larvae significantly improved survival over no treatment or an off-target ΦRGN control (log-
rank test, P < 0.001) (Fig. 3b). Moreover, ΦRGNeae was significantly more effective than 
chloramphenicol treatment, to which the EHEC strain was resistant (log-rank test, P < 0.05) 
(Supplementary Fig. 8 and Supplementary Table 1). Although ΦRGNeae treatment was 
inferior to carbenicillin, to which the bacteria were susceptible (Supplementary Fig. 8 and 
Supplementary Table 1), these data support RGNs as viable alternatives for cases where 
bacteria are highly resistant to existing antibiotics. Improvements in delivery efficiency with 
ΦRGNeae would be expected to improve treatment efficacy and outcome.
In addition to implementing targeted antimicrobial therapies, RGNs can be used to modulate 
the composition of complex bacterial populations (Fig. 4). Current therapies that use a 
prebiotic, probiotic or drug to modify the human microbiota have demonstrated potential for 
alleviating various disease states, but such therapies remain poorly characterized in terms of 
off-target effects and the specific mechanisms by which they act20. In concert with the host 
range of the delivery vehicle, RGN activity can selectively remove bacteria with specific 
genomic content. This could reduce the prevalence of unwanted genes, including antibiotic 
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resistance and virulence loci, or metabolic pathways from bacterial communities without 
affecting bystanders.
As a proof-of-principle experiment for ‘bacterial knockdowns’ using RGNs, we constructed 
a synthetic consortium comprising three phage-susceptible E. coli strains with differential 
antibiotic resistance profiles. We used β-lactam–resistant E. coli EMG2 pNDM-1, 
quinolone-resistant RFS289 (gyrAD87G) and chloramphenicol- resistant CJ236. Application 
of ΦRGNndm-1 elicited >400-fold greater killing of EMG2 pNDM-1, compared to control, 
while leaving RFS289 and CJ236 cell populations intact. Treatment with ΦRGNgyrAD87G 
resulted in >20,000-fold greater killing of RFS289, compared to control, without a 
concomitant reduction in EMG2 pNDM-1 or CJ236 (Fig. 4). These results demonstrate that 
RGNs can selectively knockdown bacteria that contain target DNA sequences, thereby 
allowing the remaining nontarget bacteria to dominate the population. Adapting this 
approach for tuning endogenous microbiota could be accomplished by delivering RGNs in 
vivo by means of broad-host-range phages or phage cocktails, or with conjugative plasmids. 
An appropriately targeted bacterial knockdown approach could be used in functional studies 
of complex microbiota and to complement additive therapies, such as probiotics, for 
microbiome-associated diseases by clearing specific niches or removing defined genes from 
bacterial populations.
In light of the rising tide of antibiotic resistance, interest in engineered cellular and viral 
therapeutics as potential biological solutions to infectious disease has resurged. By 
repurposing parts developed by nature, synthetic biologists have designed artificial gene 
circuits for antimalarial production21 and engineered probiotics22 and phage therapeutics to 
eradicate biofilms23 or potentiate antibiotic activity24,25. Here, we demonstrate that 
transmissible CRISPR-Cas systems can act as a platform for programmable antimicrobials 
that harness site-specific cleavage to induce cytotoxicity, activate toxin-antitoxin systems, 
resensitize bacterial populations to antibiotics and modulate bacterial consortia. This work 
complements the recent finding that the Vibrio cholerae phage, ICP1, encodes its own 
CRISPR-Cas system to counteract a host-encoded phage defense locus26, and that CRISPR-
Cas constructs transformed into electrocompetent cell populations are incompatible with 
cells that contain cognate target sequences11,27,28. In contrast to these other studies, we 
show that CRISPR-Cas technology can be applied both in situ for the removal of undesired 
genes from microbial populations and in vivo to treat infection in the absence of artificial 
selection. Moreover, we demonstrate that RGNs can be used to activate plasmid-borne 
toxin-antitoxin systems that have recently become an attractive antimicrobial strategy29. In 
addition to validating antimicrobial activity, we further demonstrate potential applications of 
RGNs in the deletion of plasmids from cells or the detection of DNA elements with up to 
single-nucleotide resolution using a DNA-damage-responsive reporter.
Because CRISPR-Cas systems are widely conserved in bacteria and archaea, the isolation, 
development and optimization of delivery vehicles will be required for the creation of RGNs 
capable of targeting additional strains, including multidrug-resistant pathogens as well as 
key members of endogenous microbiota. These next-generation phage systems should be 
designed with the goal of avoiding anticipated shortcomings, including host range 
limitations, phage resistance and concerns around immune reactions (Supplementary 
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Discussion). Delivery systems that function in higher organisms could also enable RGNs to 
modulate the prevalence of specific genes in wild-type populations30.
Owing to the modularity and simplicity of CRISPR-Cas engineering, libraries of 
multiplexed ΦRGNs could be rapidly constructed to simultaneously target a plethora of 
antibiotic resistance and virulence determinants and to modulate the composition of complex 
microbial communities. The addition of facile, sequence-informed, rational design to a field 
that has been dominated by time- and cost-intensive screening for broad-spectrum, small-
molecule antibiotics has the potential to reinvigorate the pipeline for new antimicrobials.
ONLINE METHODS
Strains and culture conditions
Unless otherwise noted, bacterial cultures were grown at 37 °C with Luria-Bertani (LB) 
medium (BD Difco). Bacterial strains used in this study are listed in Supplementary Table 2. 
Where indicated, antibiotics were added to the growth medium to the following final 
concentrations: 100 μg/ml carbenicillin (Cb), 30 μg/ml kanamycin (Km), 25 μg/ml 
chloramphenicol (Cm), 100 μg/ml streptomycin (Sm) and 150 ng/ml ofloxacin (Ofx).
Strain construction
E. coli EMG2 SmR was generated by plating an overnight culture of E. coli EMG2 onto LB
+Sm. Spontaneous resistant mutants were re-streaked onto LB+Sm and an isolated colony 
was picked and used as the recipient for conjugation of the multidrug resistance plasmids. 
Overnight cultures of EMG2 SmR (recipient), E. coli CDC1001728 (donor for pNDM-1) 
and K. pneumoniae K6 (donor for pSHV-18) were washed in sterile PBS and 100 μl of 
donor and recipient were spotted onto LB agar plates and incubated at 37 °C overnight. 
Transconjugants were harvested by scraping the cells in 1 ml of sterile PBS and plating onto 
LB+Sm+Cb.
The chromosomal integrations of the blaNDM-1 and blaSHV-18 β-lactamase genes and 
generation of EMG2 gyrAD87G were performed by λ-Red recombineering using the pSIM9 
system31. Templates for integration at the nonessential lacZYA locus were generated by 
amplifying the blaNDM-1 and blaSHV-18 genes from lysates of CDC1001728 and K6 using 
the primers rcD77/78 and rcD73/74, respectively. Templates for construction of EMG2 
gyrAD87G were obtained by amplifying gyrA from RFS289 using primers mmD155/161.
Plasmid construction
To generate the RGN plasmids (Supplementary Fig. 2), we created an intermediate vector 
pZA-RGNØ, which lacks a CRISPR locus. The tracrRNA and PL(tetO-1) promoter were 
synthesized (Genewiz) and amplified using primers mmD98/99, cas9 was amplified from 
pMJ806 (ref. 7) using primers mmD74/75, and the vector backbone was amplified from 
pZA11G using primers mmD82/83. Each PCR product was purified and ligated by Gibson 
assembly32. To create the final backbone vector for the RGN plasmids, the pBBR1 origin, 
chloramphenicol resistance marker, tL17 terminator, and CRISPR locus cloning site were 
amplified from an intermediate vector pBBR1-MCS1-tL17 using mmD151/154, digested 
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with NheI and SacI-HF, and ligated with pZA-RGNØ digested with SacI-HF and AvrII to 
create pZB-RGNØ. Digestion of this vector with PstI-HF and XbaI allowed for the insertion 
of assembled CRISPR loci. The tracrRNA pRGNndm-1 plasmid was created by 
amplification of pRGNndm-1 with mmD162/163, ClaI digestion, and self-ligation. The 
Cas9D10A mutant plasmid was constructed through site-directed mutagenesis of 
pRGNndm-1 with primers mmD108/109 and the KAPA HiFi PCR kit (KAPA Biosystems).
The CRISPR loci were constructed through isothermal annealing and ligation of short, 
single-stranded oligonucleotides (Integrated DNA Technologies). Each spacer and repeat 
piece was built by a corresponding oligo duplex connected to adjacent pieces by 6-bp 
overhangs. In addition, the terminal repeats were designed to contain a 17-bp extension 
comprised of a BsaI restriction site to generate an overhang that allowed insertion into the 
pUC57-Km-crRNAØ backbone vector synthesized by Genewiz. The oligos used to build 
each RGN are listed in Supplementary Tables 3 and 4.
To assemble the CRISPR loci, 500 pmol of sense and antisense oligos in a given duplex 
were annealed by boiling for 10 min at 99 °C and cooled to room temperature. 300 pmol of 
each annealed duplex were combined with 15 U of T4 polynucleotide kinase (Affymetrix), 
400 U of T4 DNA ligase (NEB), T4 ligase buffer (NEB) and ddH2O to a volume of 20 μl. 
Following incubation at 25 °C for 1 h, the reaction products were purified using a Qiagen 
QIAquick PCR Purification Kit. Purified products were digested for 3 h with BsaI-HF and 
re-purified using QIAquick. To prepare the crRNA backbone vector, pUC57-Km-crRNAØ 
was amplified using primers mmD104/105, subsequently digested with BbsI to generate 
compatible overhangs, and ligated with the assembled CRISPR loci. Positive clones of the 
CRISPR loci were digested from the entry vector using PstI-HF and XbaI and ligated into 
pZB-RGNØ digested with the same enzymes to create the final RGN plasmids.
Phagemid vector pZEf-gfp was created previously by adding the f1 origin amplified from 
the yeast shuttle pRS series33 into pZE22-gfp12. The RGN constructs consisting of the genes 
encoding the tracrRNA, Cas9 and a sequence-targeting crRNA were amplified as a single 
product from the respective pRGN vectors using KAPA HiFi polymerase (Kapa 
Biosystems) with primers rcD169/183 and digested with AvrII and XmaI (New England 
Biolabs). These inserts were ligated with a backbone derived from amplifying the 
kanamycin resistance cassette, ColE1 replication origin and the f1 origin required for 
packaging into M13 particles off of pZEf-gfp with primers rcD184/185 and digesting with 
the same enzymes. E. coli DH5αPro was transformed with ligated plasmids for sequence 
verification and plasmid purification.
The pZE-blaNDM-1-gfp and pZA-blaNDM-1-gfp vectors were constructed by swapping the 
antibiotic resistance cassette of the Lutz-Bujard vectors pZE12G and pZA12G12. The 
blaNDM-1 gene was amplified from a lysate of CDC1001728 using primers mmD8/9, and the 
PCR product was digested with SacI-HF and XhoI. The digested product was ligated into 
the Lutz-Bujard vectors digested with the same enzymes.
The PemI antitoxin complementation plasmid pZA31-pemI was created by first amplifying 
the pemI coding sequence from pSHV-18 with mmD253/254. The PCR product was 
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digested with BamHI and KpnI and ligated with the large fragment of a pZA31G digest with 
the same enzymes. The SOS-responsive pZA3LG reporter plasmid was derived from 
pZE1LG34 by swapping the origin of replication and antibiotic resistance marker with 
pZA31G using AatII and AvrII as restriction enzymes.
Mobilizable RGNs were created by first amplifying the R1162 replication origin and oriT 
using mmD266/267. The chloramphenicol selection marker and RGN locus were amplified 
from pRGNndm-1 and pRGNshv-18 with mmD247/248. PCR products were digested with 
SpeI and XmaI, ligated and used to transform E. coli S17-1 λpir to create the donor cells 
used in matings.
Minimum inhibitory concentration (MIC) determination
MICs were determined by broth microdilution using LB broth according to the CLSI 
guidelines35.
Transformation assays
Overnight cultures were diluted 1:100 in fresh LB and grown to an optical density (OD600) 
of ~0.3–0.5. Following 15 min of incubation on ice, cultured cells were centrifuged at 
3,200g, and pellets were resuspended in one tenth volume of TSS buffer (LB, 10% 
polyethylene glycol, 5% dimethyl sulfoxide, 50 mM Mg2+ at pH 6.5)36. A 100 μl aliquot of 
cells was incubated with 10 ng of RGN plasmid DNA. Plasmids were purified from the 
DH5αPro cloning host using a Qiagen QIAprep Spin Miniprep Kit and the concentration 
was determined using a Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen). Following 30 
min of incubation on ice, cells were heat shocked at 42 °C for 30 s, returned to ice for 2 min 
and recovered for 1.5 h at 37 °C in 1 ml of SOC broth (HiMedia). For the chromosomal 
target assay, serial dilutions of cells were plated on LB+Cm to select for transformants. 
Plates were incubated overnight at 37 °C, and the number of colony-forming units (CFU) 
were enumerated the following day. Transformation efficiency was used to assess whether 
the given RGN plasmid was toxic to cells and was calculated as the CFU/ml per μg of DNA 
transformed (Supplementary Fig. 2a).
For the episomal target assay (Supplementary Fig. 2b), following recovery, cultures were 
washed in fresh LB, diluted 1:100 in LB supplemented with chloramphenicol to select for 
transformants and incubated for 16 h at 37 °C. Samples were washed in sterile PBS, serially 
diluted and plated on LB+Cm and LB+Cm+Cb or analyzed by flow cytometry 
(Supplementary Fig. 4). Colonies were enumerated the following day and plasmid loss was 
inferred by calculating the ratio of CbR+CmR CFUs to CmR CFUs.
Overnight cultures of RGN transformants were also diluted 1:100 in sterile PBS, aliquoted 
in duplicates in a 96-well plate and immediately assayed using a BD LSRFortessa cell 
analyzer. Cells were consistently gated by side scatter and forward scatter across 
independent biological replicates. Fluorescence measurements were performed using a 488-
nm argon excitation laser. The GFP gate and laser voltages were initially determined using 
untreated pZE-blaZ-gfp and EMG2 cells as positive and negative controls, respectively, and 
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implemented across biological replicates. BD FACSDIVA software was used for data 
acquisition and analysis.
Sequence analysis
Escape mutants from transformation assays were re-isolated by passaging surviving colonies 
onto LB+Cm+Cb. DNA isolation for escape sequencing analysis was done by either 
extracting plasmid DNA from isolated escape mutants using the Qiagen QIAprep Spin 
Miniprep Kit or by amplifying the integrated target locus using primers mmD9/234 or 
mmD3/4 for blaNDM-1 and blaSHV-18, respectively. Sequencing was performed by Genewiz 
using the primers mmD112–115/153 and rcD11 for analysis of the RGN plasmids and 
mmD3 or mmD234 for examination of the integrated resistance genes.
Phagemid purification
Phagemids encoding the RGNs were purified using the Qiagen QIAprep Spin Miniprep Kit 
(Qiagen) and used to transform E. coli DH5αPro along with the m13cp helper plasmid for 
generation of phagemid-loaded M13 particles37. Strains were inoculated and grown 
overnight in 250 ml LB+Cm+Km to maintain M13cp and the phagemid, respectively. Cells 
were pelleted and the supernatant fluid containing the phagemid particles was passed 
through a 0.2-μm filter. For all purifications except the ΦRGNgyrAD87G purification for the 
dose-response curve, M13 phagemid particles were precipitated by the addition of 5% 
polyethylene glycol (PEG-6000) and 0.5M NaCl and incubation overnight at 4 °C (ref. 38) 
and pelleted at 12,000g for 1 h. Purified phagemid pellets were resuspended gently in 
1/100th volume of SM buffer (50 mM Tris-HCl [pH 7.5]), 100 mM NaCl, 10 mM MgSO4) 
and stored at 4 °C. For the ΦRGNgyrAD87G purification for the dose-response curve (Fig. 
2b), M13 phagemid particles were precipitated39 through the addition of concentrated HCl 
to pH 4.2 and subsequently pelleted at 13,000g for 15 min. The phagemid pellet was 
resuspended in 1/100th volume of water and concentrated NaOH was added to pH 7.0 to 
solubilize phagemid particles. Tris-HCl [pH 7.5], NaCl and MgSO4 were added to 
reconstitute the composition of SM buffer.
Titers were measured by incubating sample dilutions with E. coli EMG2 for 30 min and 
enumerating transductants by plating on LB and LB+Km. Titers were defined in TFU100/ml, 
which is the concentration of phagemid at which ~100% of a recipient population of an 
equivalent cell concentration would be transduced.
Phagemid kill assays
Cultures were inoculated and grown overnight in LB with appropriate antibiotics at 37 °C 
with shaking. The following day, overnights were subcultured 1:100 into 3 ml LB (no 
antibiotics) and grown at 37 °C with shaking until the OD600 reached ~0.8. Cultures were 
diluted into LB to ~108 CFU/ml for pNDM-1 and pSHV-18 assays (Fig. 1b, 2a) or ~106 
CFU/ml for gyrAD87G (Fig. 1c) and EHEC assays (Fig. 3a) and 245 μl of the suspension was 
added to 5 μl of purified phagemid stock in a 96-well plate and incubated static at 37 °C. 
The number of viable cells in samples at each interval during the time-course or at 2 h for 
endpoint assays was determined by serial dilution and spot plating onto LB, LB+Cb, and LB
+Km to analyze cytotoxicity, plasmid loss and phagemid delivery, respectively. Initial 
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suspensions were also diluted and plated onto LB to quantify the initial bacterial inocula. 
Colonies were enumerated after 8–9 h incubation at 37 °C to calculate cell viability 
(CFU/ml) and averaged over three independent experiments. Nonlinear curve fitting of the 
time-course to an exponential decay curve was performed using GraphPad Prism.
G. mellonella model
Larvae of the model organism G. mellonella19 were purchased from Vanderhorst Wholesale, 
Inc. (St. Marys, OH, USA) and received in the final larval instar for survival assays. Larvae 
were removed from food source, allowed to acclimate for at least 24 h at room temperature 
in the dark, and used within 4 d of receipt. For all injections, a KDS100 (KD Scientific) or 
Pump 11 Elite (Harvard Apparatus) automated syringe pump was set to dispense a 10 μl 
volume at a flow rate of ~1 μl/s through a 1-ml syringe (BD) and 26 G needle (BD). To 
prepare bacteria for injection, an overnight culture of E. coli O157:H7 43888 F′ was 
subcultured in Dulbecco’s Modified Eagle Medium (Gibco) for 4 h at 37 °C with shaking 
until OD600 ~0.6. Cultures were washed twice in PBS and diluted to a concentration of ~4 × 
105 CFU/ml. In accordance with other studies40, 20 larvae per treatment group were 
randomly selected based on size (150–250 mg) and excluded based on poor health as 
evidenced by limited activity, dark coloration or reduced turgor before experiments. Larvae 
were delivered injections without blinding of either PBS or bacteria behind the final left 
proleg. Approximately an hour after the first injection, SM buffer, antibiotic or ΦRGN 
treatment was administered behind the final right proleg (Fig. 3c, Supplementary Fig. 8). 
Larvae were incubated at 37 °C and survival was monitored at 12 h intervals for 72 h, with 
death indicated by lack of movement and unresponsiveness to touch19. Kaplan-Meier 
survival curves were generated and analyzed with the log-rank test using GraphPad Prism.
LexA reporter assay
Overnight cultures of EMG2 WT, EMG2 pNDM-1 and EMG2 gyrAD87G containing the 
SOS-responsive reporter plasmid pZA3LG were diluted 1:50 in LB and incubated with 
either SM buffer, ΦRGNndm-1 or ΦRGNgyrAD87G at MOI ~5 for 2 h at 37 °C 
(Supplementary Fig. 7). Cultures were diluted 1:5 in 250 μl of sterile PBS and analyzed 
using a BD LSR Fortessa cell analyzer, as above. BD FACSDIVA software was used for 
data acquisition and analysis was performed using FlowJo software.
Bacterial conjugation
Donor and recipient strains grown overnight in LB with appropriate antibiotics were diluted 
1:100 in fresh media and grown to an OD600 ~1. Cells were pelleted and resuspended in 
sterile PBS, and mating pairs were mixed at a donor to recipient ratio of 340 ± 66:1. Mating 
mixtures were pelleted, resus-pended in 20 μl of PBS and spotted onto nitrocellulose filters 
placed on LB agar plates. Initial bacterial suspensions were serially diluted and plated on LB 
agar plates to quantify the initial inocula. Matings proceeded at 37 °C for 3 h with a single 
mixing step. At 90 min, mating mixtures were collected by vigorously vortexing the filters 
in 1 ml sterile PBS. Cells were pelleted, resuspended in 20 μl PBS and re-seeded onto filters 
and incubated as above for the remaining 90 min. At the end of the 3 h mating, cells were 
again recovered by vigorously vortexing the filters in 1 ml sterile PBS. Mating mixtures 
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were serially diluted in PBS and plated onto LB+Cb to select for total number of Cb-
resistant recipient cells and LB+Cb+Cm to select for transconjugants. Colonies were 
enumerated following overnight incubation at 37 °C to determine viable cell counts and 
were averaged over nine independent biological replicates (Supplementary Fig. 1).
Synthetic consortia remodeling
E. coli CJ236, EMG2 pNDM-1 and RFS289 strains grown overnight in LB with appropriate 
antibiotics were diluted 1:100 into fresh LB (no antibiotics) and grown to OD600 ~0.8. 
Cultures were seeded into fresh LB such that the initial mixture contained ~1 × 106 CFU/ml 
of each strain and 245 μl of the suspension was added to 5 μl of SM buffer or purified 
ΦRGNndm-1 or ΦRGNgyrAD87G in triplicate in a 96-well plate and spotted onto LB +Cm, 
+Sm and +Ofx to quantify the initial concentration of CJ236, EMG2 pNDM-1 and RFS289, 
respectively. Samples were then incubated, plated and enumerated as in phagemid kill 
assays. The composition of the synthetic ecosystem under each treatment condition was 
determined by counting viable colonies on plates selective for each strain as above and data 
were calculated as viable cell concentration (CFU/ml) averaged over three biological 
replicates (Fig. 4).
Data analysis and statistics
All data were analyzed using GraphPad Prism version 6.0 (GraphPad Software, San Diego, 
CA, USA, http://www.graphpad.com/).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
RGN constructs delivered by bacteriophage particles (ΦRGN) exhibit efficient and specific 
antimicrobial effects against strains harboring plasmid or chromosomal target sequences. (a) 
Bacteriophage-delivered RGN constructs differentially affect host cell physiology in a 
sequence-dependent manner. If the target sequence is: (i) absent, the RGN exerts no effect; 
(ii) chromosomal, RGN activity is cytotoxic; (iii) episomal, the RGN leads to either (iiia) 
cell death or (iiib) plasmid loss, depending on the presence or absence of toxin-antitoxin 
(TA) systems, respectively. (b) Treatment of EMG2 wild-type (WT) or EMG2 containing 
native resistance plasmids, pNDM-1 (encoding blaNDM-1) or pSHV-18 (encoding 
blaSHV-18), with SM buffer, ΦRGNndm-1, ΦRGNshv-18, or multiplexed ΦRGNndm-1/
shv-18 at a multiplicity of infection (MOI) ~20 showed sequence-dependent cytotoxicity as 
evidenced by a strain-specific reduction in viable cell counts (n = 3). CFU, colony-forming 
units. (c) E. coli EMG2 WT or EMG2 gyrAD87G populations were treated with SM buffer, 
ΦRGNndm-1 or ΦRGNgyrAD87G at MOI ~20, and viable cells were determined by plating 
onto Luria-Bertani agar (n = 3).
Citorik et al. Page 15
Nat Biotechnol. Author manuscript; available in PMC 2015 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. 
Characterization of ΦRGN-mediated killing of antibiotic-resistant bacteria. (a) Time-course 
treatment of EMG2 WT or EMG2 pNDM-1 with SM buffer, ΦRGNndm-1 or ΦRGNshv-18 
at a multiplicity of infection (MOI) ~20. Data represent the fold change in viable colonies at 
indicated time points relative to time 0 h. (b) Dose-response curve of EMG2 WT and EMG2 
gyrAD87G treated with various concentrations of ΦRGNgyrAD87G for 2 h. Data represent 
fold change in viable colonies relative to samples treated with SM buffer. Error bars (a, b), 
s.e.m. of three independent biological replicates (n = 3). (c) EMG2 E. coli containing the 
natural pNDM-1 plasmid or the blaNDM-1 gene in a synthetic expression vector (pZA-ndm1-
gfp) were treated with either ΦRGNndm-1 or ΦRGNshv-18 at MOI ~ 20 and plated onto 
both nonselective LB and LB + carbenicillin (Cb) to select for blaNDM-1-containing cells. 
ΦRGNndm-1 treatment of cells harboring pNDM-1 resulted in a reduction in viability in the 
absence of selection, whereas ΦRGNndm-1 treatment of cells with pZA-ndm1-gfp 
demonstrated similar cytotoxicity only under selective pressure for maintenance of the pZA-
ndm1-gfp plasmid. (d) EMG2 pSHV-18 complemented with the cognate antitoxin (pZA31-
pemI) for the PemK toxin or a control vector (pZA31-gfp) was treated with SM buffer, 
ΦRGNndm-1 or ΦRGNshv-18. Cultures were plated on LB and LB + Cb and colonies were 
enumerated to assess cytotoxicity or plasmid loss.
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Figure 3. 
ΦRGN particles elicit sequence-specific toxicity against enterohemorrhagic E. coli in vitro 
and in vivo. (a) E. coli EMG2 wild-type (WT) cells or ATCC 43888 F′ (EHEC) cells were 
treated with SM buffer, ΦRGNndm-1 or ΦRGNeae at a multiplicity of infection (MOI) ~100 
and plated onto LB agar to enumerate total cell number or LB+kanamycin (Km) to select for 
transductants with ΦRGNs (n = 3). (b) G. mellonella larvae were injected with either PBS or 
approximately 4 × 105 colony forming units (CFU) of EHEC. Subsequent administration of 
ΦRGNeae at MOI ~30 significantly improved survival compared to SM buffer or 
ΦRGNndm-1 treatment (Log-rank test, P < 0.001). Survival curves represent an aggregate of 
four independent experiments, each with 20 worms per treatment group (n = 80).
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Figure 4. 
Programmable remodeling of a synthetic microbial consortium. A synthetic population 
composed of three different E. coli strains was treated with either SM buffer, ΦRGNndm-1, 
or ΦRGNgyrAD87G at an MOI ~100 and plated onto LB with chloramphenicol, streptomycin 
or ofloxacin to enumerate viable cells of E. coli CJ236, EMG2 pNDM-1 or RFS289 strains, 
respectively. ΦRGNndm-1 targets blaNDM-1 in EMG2 pNDM-1 and ΦRGNgyrAD87G targets 
the gyrAD87G allele in RFS289. Circle area is proportional to total population size and 
numbers represent viable cell concentrations (CFU/ml) of each strain after the indicated 
treatment. The s.e.m. based on three independent experiments is indicated in parentheses (n 
= 3).
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